GLP-1 Therapies Newsletter
Issue #46July 20, 20267 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

GLP-1 drugs started as diabetes treatments and became blockbuster weight-loss pills.

Now the evidence keeps expanding into territory nobody predicted — including your brain.

Your Mood on Ozempic: Genetic Evidence Points to Real Mental Health Benefits 🧠

  • A Mendelian randomization study — which uses genetic variants to approximate a drug's effects, reducing confounding — found that GLP-1 receptor activation was associated with a 18% lower risk of major depression and a 39% lower risk of bipolar disorder per unit drop in BMI.
  • The well-being signal was also stronger than what you'd expect from weight loss or blood sugar improvement alone, suggesting something more specific to GLP-1 receptor signaling itself.
  • Colocalization analysis found the depression and bipolar signals traced back to the GLP-1 receptor gene region with posterior probabilities above 75%, lending the finding genetic credibility.

Why it matters: Psychiatric safety has been a live concern for these drugs. This study doesn't close the debate, but it flips the default worry — the genetic signal points toward benefit, not harm.

🥉 Top 5% journal 🔗 Translational psychiatry 🗓️ Jul 13

Key Findings

Surgery vs. Pills: Bariatric Still Wins on Weight, but the Gap Is Closing 🏥

  • A meta-analysis of 14,548 patients found metabolic and bariatric surgery still outperforms GLP-1 drugs on total weight loss, but GLP-1 receptor agonists are closing the gap on metabolic outcomes like blood sugar control.
  • The comparison matters because surgery is a one-time cost with surgical risk, while GLP-1 drugs are indefinite and expensive — and the cost-effectiveness math is still unsettled.
💡 Surgery leads on weight loss, but the pharmacology gap is narrowing fast.

The Brain Region That Decides Fat vs. Sugar Satiety — Mapped 🐭

  • A preprint using optical recordings in behaving mice found that GFRAL neurons — the target of the sickness hormone GDF15 and a key node for weight-loss drugs — are activated specifically by fat consumption, not sugar.
  • "Anti-nausea" GIPR neurons, activated by sugar, directly inhibit GFRAL neurons, creating a macronutrient-specific gating system. These are the same two neuron types targeted by tirzepatide.
💡 The brain circuits behind tirzepatide's effects turn out to track fat and sugar separately.

GLP-1 Drugs Cut Alcohol-Related Hospitalizations — and the Effect Fades After Stopping 🍺

  • A Swedish register study found GLP-1 receptor agonist use was associated with fewer alcohol and substance use-related hospital admissions during treatment.
  • Critically, the protective association diminished after discontinuation — suggesting the effect is tied to active drug exposure, not a lasting behavioral reset.
💡 The alcohol benefit appears real but disappears when the drug does.
🥇 Top 1% journal 🔗 The lancet. Psychiatry 🗓️ Jul 15

Semaglutide Plus Exercise Preserves Muscle That the Drug Alone Erodes 💪

  • A study found that combining semaglutide with structured exercise helped preserve lean muscle mass that semaglutide alone tends to reduce during weight loss.
  • The combination also revealed organ crosstalk signals — biological communication between tissues — that weren't apparent with either intervention alone, though the mechanisms remain preliminary.
💡 Exercise may be the missing ingredient for protecting muscle on semaglutide.

An Oral Pill Form of GLP-1 Shows Kidney Protection in a Phase 2 Trial 💊

  • HRS-7535, a novel oral small-molecule GLP-1 receptor agonist, was tested in patients with diabetic kidney disease already on standard high-intensity treatments in a randomized, double-blind phase 2 trial.
  • The drug showed efficacy signals for kidney protection as add-on therapy — meaningful because most GLP-1 drugs are injected, and an oral non-peptide option could expand access substantially.
💡 A pill-form GLP-1 drug showed kidney benefits even on top of existing standard care.
🥈 Top 2% journal 🔗 EClinicalMedicine 🗓️ Jul 19

GLP-1 Drugs Beat SGLT2 Inhibitors on Mortality in Patients With AFib and Heart Failure 🫀

  • In a propensity-matched real-world cohort of 7,624 patients with atrial fibrillation and heart failure with preserved ejection fraction, incretin-based therapy was associated with lower all-cause mortality (5.3% vs. 7.3%) and fewer hospitalizations at one year compared to SGLT2 inhibitors.
  • Incretin-based therapy was also linked to lower rates of heart attack and fewer AF-related procedures like cardioversion.
💡 In this high-risk heart failure group, GLP-1 drugs outperformed a strong competitor drug class.
Top 20% journal 🔗 Journal of clinical medicine 🗓️ Jul 15

Implications

GLP-1 drugs now have credible signals in weight loss, heart disease, kidney disease, mental health, addiction, and reproductive health — often from very different study designs. The unresolved tension: it's still unclear how much of the benefit is driven by weight loss itself versus direct receptor signaling in specific tissues, and that distinction will determine who actually needs these drugs long-term.

Studies in this issue

Primary sources used for this newsletter.

  1. Effects of activating the glucagon-like peptide-1 receptor on mental health using genetic analysis
    main storyTranslational psychiatry2026-07-13PMID 42443148
  2. Weight loss and health results of metabolic surgery compared to GLP-1 drug treatment in 14,548 patients
    key findingJournal of laparoendoscopic & advanced surgical techniques. Part A2026-07-15PMID 42452903
  3. Links between GLP-1 receptor drugs and hospital stays for alcohol and drug problems during and after treatment
    key findingThe lancet. Psychiatry2026-07-15PMID 42456704
  4. Semaglutide and Exercise Together Help Keep Muscle and Reveal Organ Communication in Obesity
    key findingDiabetes & metabolism journal2026-07-15PMID 42449565
  5. Comparing GLP-1 or GLP-1/GIP Drugs with SGLT2 Inhibitors in Patients with Irregular Heartbeat and Preserved Heart Function
    key findingJournal of clinical medicine2026-07-15PMID 42452454
  6. Effectiveness and safety of HRS-7535, an oral diabetes drug, in people with diabetic kidney disease
    key findingEClinicalMedicine2026-07-19PMID 42472282
  7. Separate processing of body signals in the brain's area that controls vomiting and blood pressure
    key findingbioRxiv : the preprint server for biology2026-07-15PMID 42453677

Continue reading

All GLP-1 Therapies issues